---
title: "University of California Researchers Identify New Weight Loss Compound"
url: https://noti.group/university-of-california-researchers-identify-new-weight-loss-compound/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-11-20T00:19:49.000Z
updated: 2026-11-20T08:38:36.574Z
id: 24ca020c-8b92-4a4b-96c8-c768221a6e16
source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/11/261118073918.htm"
attribution: "Link to https://noti.group/university-of-california-researchers-identify-new-weight-loss-compound/ and name Noti Group when you quote or summarize this story."
---

# University of California Researchers Identify New Weight Loss Compound

A groundbreaking discovery has been made in weight loss research with the identification of a compound that enables the body to burn more fat while preserving muscle mass.

A groundbreaking discovery in weight loss research has been made by researchers at the University of California, Berkeley. They have identified a compound that enables the body to burn more fat while preserving muscle mass, addressing one of the major drawbacks of existing obesity treatments.

In experiments with mice, this innovative compound showed significant benefits, including improved blood sugar regulation and reduced levels of harmful blood fats. The obese animals lost substantial amounts of fat without experiencing a considerable reduction in lean muscle mass. Furthermore, the compound increased energy expenditure by up to 18%, which was not due to increased physical activity or body temperature.

The promising findings suggest that this new approach could be a game-changer for treating obesity, diabetes, and fatty liver disease. The experimental compound has also been found to enhance the benefits of popular weight-loss medications like Ozempic and Wegovy when used in combination.

Researchers have been working on finding a solution to address the side effects associated with current GLP-1 drugs, which have revolutionized the treatment of obesity and metabolic conditions over the past five years. These medications, marketed as Ozempic, Wegovy, Mounjaro, and Zepbound, have helped patients achieve substantial weight loss while improving their ability to regulate blood sugar.

However, these medications also have limitations, with some patients experiencing nausea and digestive problems that can make treatment difficult. Moreover, the appetite-suppressing effect of these drugs can lead to inadequate nutrition and muscle loss over time, contributing to weakness and frailty in older adults.

The researchers' discovery has sparked hope for a new generation of weight loss treatments that could provide improved outcomes with fewer side effects. While the effectiveness and safety of this compound have not yet been established in humans, further research is underway to explore its potential as a breakthrough treatment for obesity and related conditions.

Berkeley researchers took a fresh approach to weight loss by targeting energy expenditure rather than calorie intake. This innovative strategy involves increasing the amount of calories burned by the body to aid in weight reduction.

Energy expenditure encompasses the calories required for basic bodily functions, regulating metabolism, and everyday activities. By boosting this process, individuals may be able to shed pounds without relying solely on reducing their caloric intake.

According to Anders Nær, a professor of metabolic biology and nutrition at UC Berkeley, "Body weight responds to two levers: taking in fewer calories, or spending more energy." He emphasized that GLP-1s primarily focus on the first lever, so the researchers opted for the second approach.

The scientists centered their attention on a molecule called 5-tetradecyloxy-2-furoic acid (TOFA), which boasts an unusual combination of effects on the body's metabolism. TOFA has the ability to interfere with lipid production in the body.

This interference occurs through the disruption of lipid synthesis, affecting the levels of cholesterol and triglycerides within the body. Excessive amounts of certain lipids can contribute to metabolic disorders and cardiovascular disease, making this aspect of TOFA's action significant.

TOFA also activates genes involved in the uptake and utilization of fat as energy. By influencing both the production and consumption of fat, the compound creates a unique synergy that sets it apart from other potential treatments for obesity and related conditions.

The compound's impact on liver health is significant. It lowers triglyceride levels and improves characteristics associated with fatty liver disease, where excess fat accumulates in liver cells and can disrupt liver function over time.

The most notable outcome of TOFA treatment in obese mice was a reduction in body fat without substantial losses of lean muscle mass. This distinction is crucial because maintaining muscle mass is essential for overall strength, mobility, and long-term metabolic health.

Although the compound's properties were first discovered several decades ago, the latest research has uncovered new aspects that make it particularly useful for treating metabolic disease.

TOFA belongs to a group of substances known as ACC inhibitors, which interfere with enzymes responsible for manufacturing fatty acids. This effectively slows the production of certain fats in the body.

Previous ACC inhibitors have shown promise but faced significant challenges in clinical trials. One major obstacle was an unexpected side effect: increased triglyceride levels in the blood, potentially raising the risk of heart problems.

The Berkeley team's discovery revealed that TOFA has a dual action on cells. It not only inhibits ACC enzymes but also activates cellular receptors PPAR&alpha; and PPAR&delta;. These molecular switches stimulate processes that allow cells to absorb and break down fatty acids for energy production.

The researchers behind TOFA have made another significant discovery in their ongoing study of its effects on metabolism. According to Justin Y. Lee, the lead author of the research, TOFA triggers a coordinated response within cells that helps them absorb and break down fatty acids for energy production.

To see if this effect could be replicated using separate treatments, the scientists tested a combination of two compounds in mice. One compound blocked lipid production, while the other stimulated energy expenditure, but surprisingly, this dual approach didn't yield better results than TOFA alone.

TOFA's unique ability to influence multiple metabolic processes through a single molecule is likely key to its effectiveness, and this could have implications for how we develop new treatments for obesity and related conditions. The compound appears to target the energy balance equation from a different angle than existing GLP-1 medications.

These medications, found in drugs like Ozempic and Wegovy, work primarily by reducing appetite and food intake, whereas TOFA increases energy expenditure within cells. When researchers combined TOFA with semaglutide, tirzepatide, or other related compounds in mice, the results were more promising than those produced by either treatment alone.

The combination of TOFA with these GLP-1 medications led to greater improvements in body weight, blood glucose regulation, insulin levels, and triglycerides. This finding suggests that targeting calorie intake and energy expenditure simultaneously could potentially produce stronger metabolic benefits.

These results offer a glimmer of hope for people struggling with obesity and related health issues, as they indicate that treatments targeting different aspects of metabolism might work together more effectively than alone.

The researchers behind TOFA's promising results are cautious in their approach to its potential use in humans. They don't see it as a replacement for existing medications like Ozempic or Wegovy, but rather as a complementary treatment that could address obesity and related conditions through a different mechanism.

TOFA has shown the ability to work alongside GLP-1 appetite-suppressing drugs, enhancing their effects without duplicating them. This synergy suggests that TOFA could be used in conjunction with existing treatments to achieve more significant metabolic improvements.

Despite the encouraging findings from animal studies, much more research is needed before TOFA can be considered safe and effective for humans. The scientists emphasize that all the current data comes from laboratory experiments and must be replicated in human trials before any conclusions can be drawn about its potential benefits or risks.

Establishing a biotechnology company called ReRx Therapeutics will help advance the research towards clinical applications. This new venture has received support from UC Berkeley's life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck, which have provided valuable resources to move the project forward.

The creation of ReRx Therapeutics is an important step towards translating TOFA's potential into a treatment for humans. If successful, this compound could offer a new approach to weight loss that preserves muscle mass while encouraging energy expenditure.

The experimental compound's unique properties have sparked interest among researchers studying weight loss and muscle preservation. By activating a specific cellular pathway, this molecule appears to promote energy expenditure while sparing muscle mass. This selective approach could potentially offer an alternative to traditional methods of weight loss that often result in muscle atrophy.

Further investigation is needed to fully understand the compound's effects on human physiology. The research team has already demonstrated its efficacy in mice models, but more studies are required to confirm whether similar results can be achieved in humans. If successful, this development could lead to a new class of weight loss medications that minimize the risk of muscle wasting.

The potential benefits of this discovery extend beyond the realm of human health, as it also raises questions about the molecular mechanisms underlying energy expenditure and muscle function. As research continues to uncover the intricacies of cellular biology, scientists are one step closer to developing innovative solutions for improving overall well-being. This breakthrough could have a lasting impact on the field of medicine.

---
Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/11/261118073918.htm)  
Published by Noti Group: https://noti.group/university-of-california-researchers-identify-new-weight-loss-compound/
